Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event

Classifying PML risk with disease modifying therapies

(2017) Joseph R. Berger   Multiple Sclerosis and Related Disorders

Persistence and pathogenesis of the neurotropic polyomavirus JC

(2015) Hassen S. Wollebo et al.   ANNALS OF NEUROLOGY

Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years

(2015) R. F. van Vollenhoven et al.   JOURNAL OF RHEUMATOLOGY

Rituximab treatment did not aggravate ongoing progressive multifocal leukoencephalopathy in a patient with multiple sclerosis

(2015) F. Asztely et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Considerations on the appropriateness of the John Cunningham virus antibody assay use in patients with rheumatoid arthritis

(2015) Dominic Borie et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

B Cells and Progressive Multifocal Leukoencephalopathy: Search for the Missing Link

(2015) Deniz Durali et al.   Frontiers in Immunology

A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy

(2014) Salim Chahin et al.   JOURNAL OF NEUROVIROLOGY

A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification

(2013) Peter Lee et al.   JOURNAL OF CLINICAL VIROLOGY

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

(2012) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies

(2012) Eamonn S. Molloy et al.   ARTHRITIS AND RHEUMATISM

Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis

(2011) David B. Clifford   ARCHIVES OF NEUROLOGY

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))

(2010) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

(2010) P. P. Tak et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and Safety of Retreatment in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor Inhibitors: Results from the SUNRISE Trial

(2010) P. J. MEASE et al.   JOURNAL OF RHEUMATOLOGY

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

(2010) John H. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)

(2010) A. Rubbert-Roth et al.   RHEUMATOLOGY

Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis

(2009) R. M. Fleischmann   ARTHRITIS AND RHEUMATISM

Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial

(2009) Clifton O. Bingham et al.   ARTHRITIS AND RHEUMATISM

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

(2009) K. R. Carson et al.   BLOOD

Progressive multifocal leukoencephalopathy and CD4+ T-lymphocytopenia in a patient with Sjögren syndrome

(2008) Yuichi Hayashi et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES